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Yvonne Bausback, MD,* Sven Bräunlich, MD,* Henrik Ick, MD,* Johannes Schuster, MD,*
Spiridon Botsios, MD,* Hans-Joachim Kruse, MD,† Ramon L. Varcoe, MD,‡ Dierk Scheinert, MD*
Leipzig and Zschopau, Germany; and Sydney, Australia
Objectives The purpose of this study was to investigate the efficacy of drug-eluting balloons (DEBs) in the treatment of long
infrapopliteal lesions with regard to the short-term restenosis rate and midterm clinical result.
Background Restenosis rates of long-segment tibial artery disease are very high. Recently, a restenosis rate of 69% at
3 months after standard balloon angioplasty was demonstrated.
Methods Infrapopliteal angioplasty was performed with a paclitaxel-eluting balloon (In.Pact Amphirion, Medtronic, Minne-
apolis, Minnesota). Clinical and angiographic follow-up was performed at 3 months to detect binary restenosis,
and further clinical assessment was performed over a 12-month period thereafter.
Results In 104 patients, 109 limbs were treated for critical limb ischemia (82.6%) or severe claudication (17.4%). Mean
lesion length of the arteries treated was 176  88 mm. Angiography studied in 84 treated arteries at 3 months
showed a restenosis in 27.4% (19.1% had restenosis of more than 50%, and 8.3% were totally occluded) and
usually occurred focally. Only in 9.5% of all angiographically followed up arteries was the entire treated segment
restenosed or reoccluded. During a follow-up period of 378  65 days, 1 patient was lost and 17 died. Of the
91 limbs remaining in the analysis, clinical improvement was present in 83 (91.2%). Complete wound healing
occurred in 74.2%, whereas major amputation occurred in 4 patients, resulting in limb salvage of 95.6% for pa-
tients with critical limb ischemia.
Conclusions The early restenosis rate of long-segment infrapopliteal disease is significantly lower after treatment with DEBs
compared with historical data using uncoated balloons. Randomized trials are required to show whether this
difference will lead to improvement in clinical outcomes. (J Am Coll Cardiol 2011;58:1105–9) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.034Percutaneous transluminal angioplasty (PTA) is increas-
ingly used to treat infrapopliteal arterial disease. However,
the high restenosis rate is problematic, and repeat interven-
tions may be required in a significant proportion of patients
to achieve clinical goals (1,2). Drug-eluting stents have been
demonstrated to be effective in lowering the restenosis rate
below the knee (BTK) (3). Their design for coronary
arteries makes them a practical option more suited to
shorter tibial lesions. For long-segment BTK disease, drug-
eluting balloons (DEBs) have been designed to reduce the
From the *Center of Vascular Medicine, Angiology and Vascular Surgery, Park
Hospital Leipzig, Leipzig, Germany; †Outpatient Facility for Vascular Diseases
Zschopau, Zschopau, Germany; and the ‡Department of Surgery, Prince of Wales
Hospital and University of New South Wales, Sydney, Australia. Drs. Schmidt and
Scheinert are consultants for Medtronic. All other authors have reported that they
have no relationships relevant to the contents of this paper to disclose.m
Manuscript received February 14, 2011; revised manuscript received May 17, 2011,
accepted May 24, 2011.restenosis rate. Initially emerging as a new treatment option
for coronary arteries (4), they also have been studied in the
femoropopliteal segment (5,6). In our registry, we aimed to
investigate a recently approved DEB for its application in
infrapopliteal arteries.
See page 1110
Methods
Patient selection and interventional technique. Con-
secutive patients with critical limb ischemia (CLI) or severe
claudication and BTK lesions (stenosis: 70% or occlu-
sions) with a lesion length of 80 mm or more were treated
with a paclitaxel-eluting balloon (In.Pact Amphirion,
Medtronic, Minneapolis, Minnesota). The balloon is coated
with FreePac, a proprietary formulation of 3.0 g paclitaxel/m2 and urea, which serves as a hydrophilic spacer to
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of paclitaxel into the vessel wall.
Pre-dilation with an uncoated
balloon was performed to ensure
an uncomplicated insertion of
the DEB into the lesions. The
DEB diameter was 0.5 mm
larger than the uncoated balloon
to guarantee contact of the DEB
to the arterial wall. DEBs had a
diameter of 2.0 to 4.0 mm and a
length of 80 to 120 mm. If more
than 1 balloon was used per lesion, overlap of the DEBs was
5 mm. Inflation time was at least 1 min. In case of
flow-limiting dissection or residual stenosis of more than
30%, a prolonged dilation of up to 5 min was performed.
Stents were used as bailout for unsatisfactory results. Success
was defined as at least 1 infrapopliteal artery restoration in
continuity to the foot with a residual stenosis of less than
30%. Inflow lesions were treated during the same session.
Pharmacologic therapy. All patients were taking aspirin
100 mg daily. After sheath insertion, 5,000 IU heparin was
administered. After angioplasty, intra-arterial nitroglycerin
200 to 300 g was administered routinely to resolve
asospasm. Post-intervention dual antiplatelet therapy with
spirin 100 mg and clopidogrel 75 mg once daily was given
t least for 4 weeks and 100 mg aspirin was given daily
hereafter.
ndpoints. The primary endpoint was the angiographic
inary restenosis. Angiographic follow-up was scheduled 3
onths after the initial procedure according to our hospital
tandards. Selective angiographies in 2 different projections
ere evaluated by 2 investigators based on visual estimate.
inary restenosis was calculated using a 50% diameter
eduction threshold. Clinical outcome was assessed at 3 and
2 months after angioplasty. Clinical improvement was
efined as marked (50%) reduction of ulcer size or depth
r increase of at least 1 Rutherford-Becker category. Am-
utations and the necessity for target lesion revasculariza-
ion (TLR) or bypass surgery were recorded. This study was
erformed without industry financial support. Data analysis
as performed retrospectively. The registry adhered to the
equirements of the local ethics committee, and all patients
ave their written informed consent before the procedure.
tatistical analysis. Continuous data are given as mean 
D. Categorical variables are expressed as numbers and
ercentage.
esults
aseline characteristics of patients and lesions. Between
anuary 2009 and February 2010, 104 consecutive patients
eeting the inclusion criteria were studied. In these pa-
ients, 109 limbs were treated either for CLI (82.6%) or
evere claudication (17.4%). Patient characteristics are given
Abbreviations
and Acronyms
BTK  below the knee
CLI  critical limb
ischemia
DEB  drug-eluting balloon
PTA  percutaneous
transluminal angioplasty
TLR  target lesion
revascularizationn Table 1. DBefore treatment, 77.1% of the patients had complete or
unctional occlusion of all 3 infrapopliteal arteries. Mean
nfrapopliteal lesion length was 176  88 mm. The number
f arteries treated was left to the discretion of the interven-
ionalist; however, in only 5 limbs was more than 1 artery
reated.
The mean number of DEBs used per artery was 1.9
range: 1 to 5). In 28 limbs, a proximal angioplasty (all
nfrainguinal) was performed additionally during the same
ntervention using uncoated balloons.
eri-procedural outcomes. Interventional success was
chieved in all limbs, and stenting was necessary in 5 cases.
nevitable toe amputation was performed in 3 patients in the
eri-interventional period. Complications before discharge
ncluded 3 femoral pseudoaneurysms, only 1 requiring
urgical repair. One patient with an infected diabetic foot
ho was Rutherford-Becker category 6 died as a result of a
ajor amputation performed 21 days after PTA.
-month follow-up. During this period, 8 additional pa-
ients died, 7 of cardiac disease and 1 of a bronchial cancer
iagnosed before PTA. One patient was lost for follow-up.
linical improvement in the remaining 94 patients was seen
n 75.8% of the treated limbs, 22.2% were unchanged, and
.0% were clinically worse. Three additional toe amputa-
ions were performed. Complete wound healing was noted
n 41.9% of the Rutherford-Becker category 5 limbs.
wenty patients declined to undergo repeat angiography.
here was no difference in lesion characteristics or 3-month
linical outcomes between the patients with or without
epeat angiography.
ubgroup of angiographically examined patients at
months. Angiography at 3 months was performed in 74
atients with 79 treated limbs and 84 arteries treated with
EBs. Lesion characteristics are given in Table 2. Before
TA, target arteries were stenosed in 38.1% and were
ccluded in 61.9%. Angioplasty was performed for 55 de
Demographic Patient DataTable 1 Demographic Patient Data
Age (yrs) 73.6 6.7
Male 69 (66.3%)
Arterial hypertension 95 (91.3%)
Diabetes mellitus 74 (71.1%)
Smoking habit 32 (30.8%)
Hypercholesterolemia 68 (65.4%)
Obesity 33 (31.7%)
Coronary artery disease 47 (45.9%)
NYHA functional classes III and IV 23 (22.1%)
Renal insufficiency (GFR 60 ml/min/1.73 m2) 48 (46.2%)
Cerebrovascular disease 19 (18.3%)
Rutherford-Becker category 6 1 (0.9%)
Rutherford-Becker category 5 70 (64.2%)
Rutherford-Becker category 4 19 (17.45%)
Rutherford-Becker category 3 19 (17.45%)
Values are mean  SD or n (%).
GFR  glomerular filtration rate calculated by MDRD formula (Modification of Diet in Renal
isease); NYHA  New York Heart Association.
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Mean lesion length was 173  87 mm and mean DEB
diameter was 2.72  0.41 mm. Bailout stenting was
erformed in 5 cases. Cypher stents (Cordis, Miami, Flor-
da) were used in 3 cases, and self-expanding nitinol stents
Maris Deep, Medtronic) were used in 2 cases. Full lesion
overage was performed in 1 of the cases.
Angiography at 3 months (mean 98  22 days) found 61
(72.6%) of 84 arteries free of significant restenosis. In
27.4%, a restenosis of more than 50% was found (19.1% had
a restenosis and 8.3% were occluded). In most of these
cases (61%), restenosis developed only focally (20% of
the length of the initial target lesion) (Fig. 1). Restenosis
or reocclusion of the entire target lesion occurred only in
8 (9.5%) of the 84 treated arteries. Higher restenosis rates
were seen after treatment of distal segments, especially
when foot arteries were involved (Table 2). Two (2.4%)
of the 84 treated arteries became ectatic within the
treated segment (less than double of the reference vessel
diameter), and 1 was associated with restenosis. Clinical
improvement in limbs with restenosis was similar to that
of those without.
Midterm clinical follow-up. After a mean follow-up of
378  65 days, 86 patients with 91 treated limbs were
evaluated clinically. Clinical improvement occurred in
91.2% of these limbs. No bypass surgery was performed
during the entire study period. TLR was performed in
17.3%. Limb salvage was achieved in 95.6% of the CLI
patients and complete wound healing occurred in 74.2% of
the patients with Rutherford-Becker category 5 at baseline.
Eight additional patients died, all for unrelated reasons,
resulting in a mortality rate of 16.3% at 1 year. There were
4 unplanned amputations during this period, 1 single toe
amputation, 1 forefoot amputation, and 2 major BTK
amputations. The Rutherford-Becker categories of all pa-
tients before and after 1 year are shown in Figure 2.
Discussion
The restenosis rate after PTA of infrapopliteal arteries is
Location of Angioplasty of Patients Who Underwent3-Month Angio ra hy and Rest osis Rate inRel i to the Tre ted Artery a d Site of thTre ted Segm nt
Table 2
Location of Angioplasty of Patients Who Underwent
3-Month Angiography and Restenosis Rate in
Relation to the Treated Artery and Site of the
Treated Segment
Artery or Site Involved in PTA n (%) Restenosis (%)
Distal popliteal artery 11 (13.1) 1 (9.1)
Anterior tibial artery 48 (57.1) 15 (31.3)
Tibioperoneal trunk 18 (21.4) 3 (16.7)
Posterior tibial artery 16 (19.0) 5 (31.3)
Peroneal artery 18 (21.4) 3 (16.7)
Proximal segment of tibial arteries 54 (64.3) 5 (9.3)
Mid segment of tibial arteries 45 (53.6) 9 (20.0)
Distal segment of tibial arteries 37 (44.0) 7 (18.9)
Arteries distal to the malleolus 13 (15.5) 5 (38.5)
PTA  percutaneous transluminal angioplasty.very high. In a series recently published treating infrapop-Figure 1 Focal Restenosis at 3 Months
(A) Angiographic image showing total occlusion of the anterior tibial artery left
leg (dashed line and arrows). (B) Angiographic image obtained after angio-
plasty of the anterior tibial artery with drug-eluting balloons. (C) Angiographic
image obtained after 3 months showing a focal restenosis (arrow).
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uncoated low-profile balloons, we demonstrated an angio-
graphic restenosis rate of 69% at 3 months (2). Because of
this finding, we selected long BTK lesions for treatment
with the recently approved infrapopliteal DEB (In.Pact
Amphirion). The mean lesion length of 173 mm in this
series is comparable in length with that of our previous study
(2). The 3-month restenosis rate of 27% after treatment
with DEB represents a dramatic reduction for restenosis of
61% from the 69% seen in the series using uncoated
balloons (2). In addition, we observed an altered pattern of
recurrent disease that favored the DEB. Whereas restenosis
usually involved the whole treated segment with uncoated
balloons (2), restenosis after DEB was found to be focal,
involving 20% of the length of the target lesion in more
han 60% of the restenosed vessels. This pattern of shorter
estenosis may have less impact on flow compared with the
iffuse type and also simplifies TLR.
Although our series is too small to perform a meaningful
ubanalysis of factors that may influence patency after PTA
ith DEBs, the most distal lesions seem to perform worst. For
EB angioplasty distal to the malleolus, we found a restenosis
ate of 38.5% at 3 months. This is consistent with other
ublished series that recognize standard balloon angioplasty for
edal arteries to be a predictor of limb loss (1). The high
estenosis rate we observed in this region may be a contributing
actor.
afety of DEBs in BTK arteries. We found nothing to
ndicate the use of DEBs BTK to be unsafe. An amputation
ate of 4.4% is very acceptable for CLI patients. During the
-month angiogram, 2 arteries became moderately ectatic
ithin the treated segment, which resulted in no adverse
linical events. This has not been described previously for
EBs for other arteries. We do not believe that this
bservation raises concerns regarding the safety of DEBs in
Figure 2 Midterm Clinical Outcome
Bar graph showing Rutherford-Becker categories at baseline and
12.5 months of follow-up (FU).he infrapopliteal circulation.linical results. Multiple factors contribute to wound heal-
ng and limb salvage, including local wound care and surveil-
ance regimen, which may be equally as important as revascu-
arization. It therefore may be difficult to prove the superiority
f the DEBs over uncoated balloons for these clinical end-
oints. In fact, similar favorable results for wound healing and
imb salvage have been described after plain old balloon
ngioplasty of long infrapopliteal disease (2,7). TLRs fre-
uently are needed after endovascular treatment of BTK
rteries (1,2) and therefore may be considered a more useful
linical endpoint. Compared with the TLR rate of 50% in our
eries using uncoated balloons (2), the use of DEBs resulted in
TLR rate of 17.3%, a considerable reduction of 65.4%. It is
ith regard to TLR that the use of DEBs has most potential
o improve clinical outcomes compared with standard balloons.
osts are likely to play an important role for the use of DEB;
owever, the potential reduction in number of reinterventions
lso must be considered in these calculations if we are to
ompare DEBs with uncoated balloons.
tudy limitations. Quantitative angiography to determine
egree of restenosis in long BTK lesions is technically very
hallenging. In practice, however, the visual assessment of
ngiography was believed to be significantly more precise
han the alternatives of duplex ultrasound, magnetic reso-
ance angiography, or computed tomography angiography.
nly 1 DEB, the In.Pact Amphirion, was approved for
eripheral artery application in Europe and therefore was
he only one used during the study period. Other DEBs may
ead to differing results in the future.
onclusions
his first report of the use of DEBs BTK suggests that they are
afe and effective in this arterial region. When compared with
series using uncoated balloons, the data presented here
emonstrate a marked, more than 60% reduction in the
estenosis rate at 3 months. In addition, if restenosis occurred,
t was associated with a favorable, focal pattern. The 1-year
linical results are promising and seem to confer a durable
enefit. Further evidence, in the form of randomized con-
rolled trials, is required to confirm whether DEBs are superior
o the standard treatment of plain old balloon angioplasty in
atients with CLI from BTK disease.
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